Nabumetone

Spezifikationen

42924-53-8CAS-Nummer

641-917-1EG-Nummer

4-(6-methoxynaphthalen-2-yl)butan-2-oneIUPAC-Name

C15H16O2Chemische Formel

228.29 g/molMolekulargewicht

nabumetone; 42924-53-8; 4-(6-methoxynaphthalen-2-yl)butan-2-one; Relafen; Nabumetona; 4-(6-Methoxy-2-naphthyl)-2-butanone; nabumeton; Nabumetonum; BRL-14777; 4-(6-Methoxy-2-naphthalenyl)-2-butanone; DTXSID4045472; 2-Butanone, 4-(6-methoxy-2-naphthalenyl)-; LW0TIW155Z; NSC-758623; CHEBI:7443; DTXCID2025472; Nabumetone [USAN:USP:INN:BAN:JAN]; ApoNabumetone; Rhoxal nabumetone; Nabumetone (USAN:USP:INN:BAN:JAN); Nabumetone 500 mg; Nabumetone 750 mg; RELAFEN DS; Nabumetone 1000 mg; RefChem:55684; M01AX01; 641-917-1; Arthaxan; Relifen; Relifex; Listran; Consolan; Balmox; Nabumetonum [INN-Latin]; 4-(2-Methoxynaphthalen-6-yl)butan-2-one; Nabuser; BRL 14777; MFCD00079518; MLS000069541; BRL14777; Mebutan; Relif; SMR000058835; Dolsinal; Flambate; Unimetone; Prodac; 4-(6-methoxy-2-naphthyl)butan-2-one; NCGC00016853-01; CAS-42924-53-8; SR-01000759138; UNII-LW0TIW155Z; BRN 2103472; CCRIS 8108; Nabumetone CRS; Nabumatone Form II; Relafen (TN); Nabumetone (Standard); Spectrum_001486; NABUMETONE [MI]; Opera_ID_765; NABUMETONE [INN]; NABUMETONE [JAN]; Prestwick0_000909; Prestwick1_000909; Prestwick2_000909; Prestwick3_000909; Spectrum2_001969; Spectrum4_000174; Spectrum5_001286; NABUMETONE [USAN]; NABUMETONE [VANDF]; cid_4409; NABUMETONE [MART.]; SCHEMBL2256; CHEMBL1070; NABUMETONE [USP-RS]; NABUMETONE [WHO-DD]; BSPBio_000758; KBioGR_000687; KBioSS_001966; MLS001076325; BIDD:GT0104; DivK1c_000850; SPECTRUM1503650; SPBio_002097; SPBio_002957; Nabumetone, analytical standard; BPBio1_000834; GTPL7245; Nabumetone (JP17/USP/INN); Nabumetone - Bio-X trade mark; orb1225067; orb1309207; orb3025300; NABUMETONE [ORANGE BOOK]; SCHEMBL18096515; SCHEMBL29373228; SCHEMBL29570823; BDBM40128; HMS502K12; HY-B0559R; KBio1_000850; KBio2_001966; KBio2_004534; KBio2_007102; MSK7165; NABUMETONE [EP MONOGRAPH]; NABUMETONE [USP IMPURITY]; NINDS_000850; HMS1570F20; HMS1922G10; HMS2090D13; HMS2093I05; HMS2097F20; HMS2230H12; HMS3259I16; HMS3652M04; HMS3714F20; HMS3885A22; HMS5082E04; NABUMETONE [USP MONOGRAPH]; Pharmakon1600-01503650; HY-B0559; Tox21_110647; CCG-39507; EBC-26251; NSC758623; s4051; AKOS009529199; MSK7165-1000A; Tox21_110647_1; DB00461; FN26115; KS-1371; NC00579; NSC 758623; IDI1_000850; NCGC00016853-02; NCGC00016853-03; NCGC00016853-05; NCGC00016853-06; NCGC00016853-13; NCGC00095063-01; NCGC00095063-02; AC-19025; BN166181; 1-(2'-Methoxynaphth-6'-yl)butan-3-one; SBI-0051869.P002; AB00052392; NS00003590; SW197312-3; D00425; L10109; AB00052392-13; AB00052392_14; AB00052392_15; EN300-1853581; Nabumetone Solution in Acetonitrile, 1000ug/mL; F211337; Q425207; SR-01000759138-2; SR-01000759138-3; BRD-K65146499-001-04-8; BRD-K65146499-001-14-7; BRD-K65146499-001-26-1; BRD-K65146499-001-27-9; Nabumetone, British Pharmacopoeia (BP) Reference Standard; Nabumetone, European Pharmacopoeia (EP) Reference Standard; Nabumetone, United States Pharmacopeia (USP) Reference StandardSynonyme